A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HMPL-453 (FGFR Inhibitor) Combined With Chemotherapy or Anti-PD-1 Antibody in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Hmpl 453 (Primary) ; Tislelizumab (Primary) ; Antineoplastics
Indications Adenocarcinoma; Bladder cancer; Cholangiocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors HUTCHMED

04 Mar 2022 Planned primary completion date changed from 1 Mar 2024 to 1 Sep 2024.
04 Mar 2022 Status changed from not yet recruiting to recruiting.
10 Dec 2021 Status changed from planning to not yet recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com